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Aims To assess whether radial compared with femoral access is associated with consistent outcomes in patients with
ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome
(NSTE-ACS).
...................................................................................................................................................................................................
Methods
and results
In the Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of
angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 ra-
dial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major ad-
verse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical
events (NACE), defined as MACE or major bleeding In the overall study population, radial access reduced the
NACE but not MACE endpoint at the prespecified 0.025 alpha. MACE occurred in 121 (6.1%) STEMI patients with
* Corresponding author. Tel: þ41 31 632 96 53, Fax: þ41 31 632 47 71, Email: marco.valgimigli@insel.ch
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radial access vs. 126 (6.3%) patients with femoral access [rate ratio (RR) = 0.96, 95% CI = 0.75–1.24; P = 0.76] and
in 248 (11.3%) NSTE-ACS patients with radial access vs. 303 (13.9%) with femoral access (RR = 0.80, 95%
CI = 0.67–0.96; P = 0.016) (Pint = 0.25). NACE occurred in 142 (7.2%) STEMI patients with radial access and in
165 (8.3%) patients with femoral access (RR = 0.86, 95% CI = 0.68–1.08; P = 0.18) and in 268 (12.2%) NSTE-ACS
patients with radial access compared with 321 (14.7%) with femoral access (RR = 0.82, 95% CI = 0.69–0.97;
P = 0.023) (Pint = 0.76). All-cause mortality and access site-actionable bleeding favoured radial access irrespective
of ACS type (Pint = 0.11 and Pint = 0.36, respectively).
...................................................................................................................................................................................................
Conclusion Radial as compared with femoral access provided consistent benefit across the whole spectrum of patients with
ACS, without evidence that type of presenting syndrome affected the results of the random access allocation.
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Introduction
Advances in antithrombotic therapy in patients with acute coronary
syndrome (ACS), along with an early invasive strategy in high-risk pa-
tients, have reduced the incidence of recurrent ischaemic events but
also increased bleeding complications.1 Bleeding is associated with
short-term and long-term hazards for mortality, albeit the exact na-
ture of this relationship remains speculative.1–3
The Minimizing Adverse Haemorrhagic Events by TRansradial
Access Site and Systemic Implementation of angioX (MATRIX) trial is
the largest randomized trial to compare radial and femoral access in
largely unselected patients with ACS with or without ST-segment ele-
vation myocardial infarction (STEMI) undergoing coronary angiography
and percutaneous coronary intervention (PCI). MATRIX-Access
observed a numerical reduction of major adverse cardiovascular events
(MACE) in favour of radial access, which did not reach the prespecified
0.025 alpha thresholds for statistical significance. However, the use of
radial access significantly reduced the rate of net adverse clinical events
(NACE), defined as the composite of MACE or major bleeding.
The RIVAL (A Trial of Trans-radial Versus Trans-femoral PCI
Access Site Approach in Patients With Unstable Angina or Myocardial
Infarction Managed With an Invasive Strategy) study reported incon-
sistent results in terms of the primary endpoint as well for mortality
depending on presentation syndrome, namely non-ST-segment eleva-
tion ACS (NSTE-ACS) or STEMI.4 Therefore, it remains unclear
whether radial access should be preferred over femoral access across
the entire spectrum of ACS patients.
We had prespecified to analyse the consistency of risks and bene-
fits of each access site in patients with NSTE-ACS and STEMI
undergoing invasive management.
Methods
Study design
The MATRIX-Access was conceived as a randomized, multicentre, superior-
ity trial-comparing radial with femoral access in patients with ACS with or
without STE who were about to undergo coronary angiography and PCI, if
indicated.5,6 This was the first of three trials of the MATRIX programme
(registered with clinicaltrials.gov; Unique identifier: NCT01433627) and was
performed in all patients with an ACS consenting to participate in the pro-
gramme. The trial was approved by the institutional review board at each par-
ticipating centre, and all patients gave written informed consent to participate.
Study patients
Patients were eligible if they had an ACS with or without ST-segment ele-
vation (STE), were scheduled to undergo an invasive approach, and the
interventional cardiologist was willing to proceed with either radial or
femoral access with expertise for both, including at least 75 coronary
interventions performed and at least 50% of interventions in ACS via the
radial route during the previous year. Patients presenting with NSTE-
ACS were eligible if they had a history consistent with new or worsening
ischaemia, occurring at rest or with minimal activity within 7 days before
randomization, and fulfilled at least two high-risk criteria (detailed in the
web extra material). Patients with STEMI were eligible if they presented
within 12 h of the onset of symptoms or between 12 and 24 h after symp-
tom onset if there was evidence of continued ischaemia or previous
fibrinolytic treatment and if they had STE of at least 1 mm in two or more
contiguous leads, new left bundle-branch block, or true posterior MI. The
main inclusion and exclusion criteria were previously reported.5,6
Study protocol and randomization
Before the start of angiography, patients were randomly assigned 1:1 to ra-
dial or femoral access for diagnostic angiography and PCI, if indicated, using
a web-based system to ensure adequate concealment of allocation. The
randomization sequence was computer generated, blocked, and stratified
by site, intended new or ongoing use of ticagrelor or prasugrel, type of
ACS (STEMI or troponin-positive or -negative NSTE-ACS), and anticipated
use of immediate PCI. Access site management during and after the diag-
nostic or therapeutic procedure was left to the discretion of the treating
physician, and closure devices were allowed as per local practice. The use
of anticoagulants outside the protocol of the MATRIX programme was not
allowed. Bivalirudin administration was consistent with the approved prod-
uct labeling, whereas unfractionated heparin was dosed at 70–100 U/kg in
patients not receiving glycoprotein IIb/IIIa inhibitors and at 50–70 U/kg in
patients receiving glycoprotein IIb/IIIa inhibitors. Use of all other antithrom-
botic medications, including oral antiplatelet agents and non-antithrombotic
medications, such as beta-blockers, angiotensin-converting enzyme inhibi-
tors, and other antihypertensive agents, were allowed as per guidelines.7
Study outcomes
Two co-primary 30-day composite outcomes were pre-specified: MACE,
defined as the composite of all-cause mortality, MI, or stroke; and
NACE, defined as the composite of non-coronary artery bypass
grafting (CABG)-related major bleeding (Bleeding Academic Research
Consortium, BARC type 3 or 5) or MACE.8 Secondary outcomes
included each component of the composite outcomes, cardiovascular
mortality, and stent thrombosis. Bleeding was also assessed and adjudi-
cated on the basis of the TIMI and GUSTO scales.9,10 Stent thrombosis
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Table 1 Baseline characteristics of the intention-to-treat population according to initial clinical presentation (STEMI,
NSTE-ACS) and access site
Baseline characteristics STEMI NSTE-ACS
Radial access
(n 5 2001)
Femoral access
(n 5 2009)
P-value Radial access
(n 5 2196)
Femoral access
(n 5 2198)
P-value
Age—years 63.7 ± 12.1 64.0 ± 12.1 0.43 67.2 ± 11.3 67.5 ± 11.3 0.33
>_75 years 424 (21.2) 444 (22.1) 0.48 644 (29.3) 658 (29.9) 0.66
Male sex 1552 (77.6) 1541 (76.7) 0.52 1574 (71.7) 1505 (68.5) 0.020
Weight (kg) 77.4 ± 13.9 77.7 ± 13.4 0.52 77.4 ± 14.4 76.4 ± 13.7 0.024
Body mass index (kg/m<_) 26.9 ± 4.0 27.1 ± 4.1 0.22 27.2 ± 4.3 27.1 ± 4.3 0.22
Diabetes mellitus 371 (18.5) 352 (17.5) 0.013 588 (26.8) 592 (26.9) 0.42
Insulin-dependent 64 (3.2) 91 (4.5) 0.42 145 (6.6) 166 (7.6) 0.42
Current smoker 821 (41.0) 814 (40.5) 0.90 638 (29.1) 614 (27.9) 0.64
Hypercholesterolemia 754 (37.7) 814 (40.5) 0.066 1045 (47.6) 1078 (49.0) 0.33
Hypertension 1093 (54.6) 1141 (56.8) 0.70 1532 (69.8) 1545 (70.3) 0.70
Family history of coronary artery disease 557 (27.8) 567 (28.2) 0.79 589 (26.8) 580 (26.4) 0.74
Previous myocardial infarction 198 (9.9) 186 (9.3) 0.49 387 (17.6) 432 (19.7) 0.084
Previous PCI 215 (10.7) 171 (8.5) 0.017 395 (18.0) 414 (18.8) 0.47
Radial access 38 (1.9) 18 (0.9) 0.0068 81 (3.7) 66 (3.0) 0.21
Femoral access 94 (4.7) 83 (4.1) 0.38 182 (8.3) 203 (9.2) 0.27
Both radial and femoral access 8 (0.4) 5 (0.2) 0.40 28 (1.3) 30 (1.4) 0.79
Access site unknown 75 (3.7) 65 (3.2) 0.38 104 (4.7) 115 (5.2) 0.45
Previous CABG 27 (1.3) 25 (1.2) 0.77 84 (3.8) 121 (5.5) 0.0083
Previous TIA or stroke 78 (3.9) 94 (4.7) 0.22 117 (5.3) 136 (6.2) 0.22
Peripheral Vascular Disease 106 (5.3) 123 (6.1) 0.26 235 (10.7) 249 (11.3) 0.51
Chronic Obstructive Pulmonary Disease 91 (4.5) 94 (4.7) 0.84 159 (7.2) 189 (8.6) 0.096
History of renal failure 14 (0.7) 31 (1.5) 0.011 32 (1.5) 28 (1.3) 0.60
Dialysis 1 (0.0) 2 (0.1) 1.00 3 (0.1) 2 (0.1) 0.69
Clinical presentation
Cardiac arrest 71 (3.5) 68 (3.4) 0.78 14 (0.6) 15 (0.7) 0.85
Killip class
I 1775 (88.7) 1817 (90.4) 0.072 2021 (92.0) 1983 (90.2) 0.035
II 142 (7.1) 144 (7.2) 0.93 126 (5.7) 157 (7.1) 0.058
III 45 (2.2) 22 (1.1) 0.0044 43 (2.0) 57 (2.6) 0.16
IV 39 (1.9) 26 (1.3) 0.10 6 (0.3) 1 (0.0) 0.070
Previous lyctic therapy 94 (4.7) 103 (5.1) 0.53 0 (0.0) 1 (0.0) 1.00
Systolic arterial pressure (mmHg) 136.0 ± 27.0 136.2 ± 26.9 0.76 140.8 ± 23.9 141.2 ± 24.2 0.58
Heart rate (min-1) 77.2 ± 17.3 77.0 ± 17.1 0.78 75.6 ± 15.8 75.1 ± 16.5 0.38
Left ventricular ejection fraction (%) 49.2 ± 9.5 48.6 ± 9.5 0.030 53.2 ± 9.2 52.9 ± 9.6 0.44
eGFR 85.2 ± 25.7 84.5 ± 25.6 0.36 83.2 ± 25.2 82.3 ± 25.4 0.21
eGFR < 60 310 (15.7) 298 (15.0) 0.55 390 (17.8) 417 (19.1) 0.29
eGFR < 30 18 (0.9) 27 (1.4) 0.18 17 (0.8) 22 (1.0) 0.42
Medications administered before the cath-Lab
Aspirin 1865 (93.2) 1881 (93.6) 0.59 2091 (95.2) 2073 (94.3) 0.18
Clopidogrel 734 (36.7) 738 (36.7) 0.97 1281 (58.3) 1259 (57.3) 0.48
Prasugrel 402 (20.1) 395 (19.7) 0.73 83 (3.8) 73 (3.3) 0.41
Ticagelor 378 (18.9) 394 (19.6) 0.56 600 (27.3) 635 (28.9) 0.25
Enoxaparin 57 (2.8) 91 (4.5) 0.0048 630 (28.7) 651 (29.6) 0.50
Fondaparinux 55 (2.7) 68 (3.4) 0.24 373 (17.0) 400 (18.2) 0.29
ACE inhibitors 273 (13.6) 278 (13.8) 0.86 980 (44.6) 1023 (46.5) 0.20
Angiotensin II receptor antagonist 135 (6.7) 141 (7.0) 0.73 315 (14.3) 321 (14.6) 0.81
Statins 403 (20.1) 410 (20.4) 0.83 1409 (64.2) 1453 (66.1) 0.18
Beta blockers 412 (20.6) 432 (21.5) 0.48 1282 (58.4) 1343 (61.1) 0.066
Warfarin 20 (1.0) 16 (0.8) 0.50 52 (2.4) 48 (2.2) 0.68
Continued
MATRIX access trial and type of ACS 1071
..
..
..
..
..
..
was defined as the definite or probable occurrence of a stent-related
thrombotic event according to the Academic Research Consortium clas-
sification.11 All outcomes were pre-specified.5 An independent clinical
events committee blinded to treatment allocation adjudicated all sus-
pected outcome events by reviewing relevant medical records after site
monitoring by Trial Form Support (Lund, Sweden) in Italy and the
Netherlands, FLS-Research Support (Barcelona, Spain) in Spain, and
Gothia Forum (V€astra Götaland) in Sweden.
Statistical analysis
Statistical analyses were performed by an academic statistical group led
by two of the authors, who had access to the full de-identified data set.
All analyses were performed according to the intention-to-treat prin-
ciple, including all patients in the analysis according to the allocated ac-
cess. Events up to 30 days post-randomization were considered. We
analysed primary and secondary outcomes separately for STEMI and
NSTE-ACS as time to first event using the Mantel–Cox method, accom-
panied by log-rank tests to calculate corresponding two-sided P-values.
We did not perform any adjustments for multiple comparisons but set
the alpha error at 2.5% to correct for the two co-primary outcomes.
Survival curves were constructed using Kaplan–Meier estimates. We per-
formed stratified analyses according to pre-specified subgroups including
age, sex, body mass index (BMI), type of P2Y12 inhibitor used, both over-
all and radial PCI volume by centre, renal function, diabetes, and periph-
eral vascular disease, and estimated possible interaction terms or trends
across ordered groups separately for the STEMI and NSTE-ACS study
populations. Although included in the statistical analysis plan, neither the
STE-ACS analysis nor its subsets were separately powered to detect ef-
fects on clinical outcomes by the access strategy. All analyses were per-
formed using the statistical package Stata 14.1 and R 3.3.0
Results
The MATRIX trial enrolled 8404 patients with ACS from 78 centres
in Italy, the Netherlands, Spain, and Sweden between October 2011
and July 2014. Of these patients, 4010 (47.8%) fulfilled the definition
for STEMI (radial: 2001, 23.8%; femoral: 2009, 23.9%) (see
Supplementary material online, eFigure S1 and S2), and 4394 (52.2%)
patients presented with NSTE-ACS (radial 2196, 26.1%; femoral
2198, 26.1%). Complete follow-up throughout 30 days was available
in 4191 radial and 4196 femoral patients. Baseline characteristics
were generally well balanced between randomization groups
according to access site, considering the initial clinical presentation
(STEMI and NSTE-ACS) (Table 1).
Procedural results according to clinical presentation and access
site are presented in Supplementary material online, eTable S1. PCI
..................................................................... .....................................................................
....................................................................................................................................................................................................................
Table 1 Continued
Baseline characteristics STEMI NSTE-ACS
Radial access
(n 5 2001)
Femoral access
(n 5 2009)
P-value Radial access
(n 5 2196)
Femoral access
(n 5 2198)
P-value
PPI 640 (32.0) 652 (32.5) 0.75 1518 (69.1) 1540 (70.1) 0.50
Previous unfractionated heparin 952 (47.6) 949 (47.2) 0.83 287 (13.1) 288 (13.1) 0.97
Bivalirudin 2 (0.1) 1 (0.0) 0.62 2 (0.1) 1 (0.0) 0.62
Glycoprotein IIb/IIIa inhibitors 2 (0.1) 1 (0.0) 0.62 6 (0.3) 5 (0.2) 0.77
Depicted are frequencies n (%) or means (SD), P-values come from t-test and v2 or Fisher’s exact test.
STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation acute coronary syndrome; CABG, coronary artery bypass grafting; eGFR, estimated
glomerular filtration rate; PPI, proton pump inhibitor; TIA, transient ischaemic attack.
Figure 1 (A) All-cause mortality, myocardial infarction, or stroke,
and (B) all-cause mortality, myocardial infarction, stroke, or Bleeding
Academic Research Consortium 3 or 5 bleeding. Red lines illustrate
patients randomized to femoral access and blue lines correspond to
the patients randomized to radial access. Thick lines correspond to
the NSTE-ACS patients and thin lines stand for the STEMI popula-
tion. MI, myocardial infarction; TFA, trans femoral access; TRA,
trans radial access; NSTE-ACS, non-ST-segment elevation acute
coronary syndrome; STEMI, ST-segment elevation myocardial
infarction.
1072 P. Vranckx et al.
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..was attempted in more than 90% in STEMI and in 70% of NSTE-
ACS patients in both access groups. There was a highly significant
qualitative interaction between crossover rates and clinical presenta-
tion [P-value for interaction (Pint) < 0.0001], with 4.5% of the NSTE-
ACS patients and 7.2% of the STEMI patients who received interven-
tion via femoral access against the original random allocation to radial
as compared with 2.9% of the NSTE-ACS patients and 1.6% of the
STEMI patients who received intervention via radial access in the
femoral group (see Supplementary material online, eTable S1).
There were significant interactions noted for left main coronary ar-
tery lesion location, which underwent slightly more frequent treat-
ment in the radial arm of STEMI patients (Pint = 0.024), and for TIMI
2 flow post procedure (Pint = 0.033) being more frequently
observed in STEMI as compared with NSTE-ACS patients irrespect-
ive of the allocated access group.
Medications at presentation (Table 1), during intervention (see
Supplementary material online, eTable S1), or at discharge (see
Supplementary material online, eTable S2) were well matched with the
only exception for sub-therapeutic dosing of unfractionated heparin
(<50 U/kg), which was more often implemented in NSTE-ACS patients
in both access site groups as compared with STEMI (Pint < 0.0001).
Clinical outcomes
For the co-primary outcomes of major adverse cardiac events and
NACE, there were no significant interactions between the access site
and type of ACS (STEMI or NSTE-ACS patients) (Pint = 0.25 and
0.76, respectively) (Figure 1, see Supplementary material online,
eFigure S3).
In particular, the first co-primary outcome MACE occurred in 121
(6.1%) STEMI patients with radial access and in 126 (6.3%) patients
Figure 2 Non-ST-segment elevation acute coronary syndrome. ST, segment elevation myocardial infarction. *P-values are for trend across
ordered groups. ACS, acute coronary syndrome; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial infarction. *P-values are for trend across ordered groups.
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..with femoral access [rate ratio (RR) = 0.96, 95% CI = 0.75–1.24].
Among NSTE-ACS patients, MACE events occurred in 248 (11.3%)
patients randomly assigned to radial access, compared with 303
(13.9%) patients assigned to femoral access (RR = 0.80, 95% CI =
0.67–0.96) (Table 2). The second co-primary outcome NACE was
observed in 142 (7.2%) patients with radial access vs. in 165 (8.3%)
patients with femoral access (RR = 0.86, 95% CI = 0.68–1.08) among
the STEMI group, and in 268 (12.2%) patients with radial access vs.
321 (14.7%) patients with femoral access (RR = 0.82, 95% CI = 0.69–
0.97) in the NSTE-ACS population (see Supplementary material on-
line, eFigure S4 and Table 2).
There was no significant interaction between access site and clin-
ical presentation with respect to any other ischaemic secondary end-
point. All-cause and cardiovascular mortality, which numerically
favoured the radial access, were significantly reduced in in the NSTE-
ACS group undergoing radial access (RR = 0.50, 95% CI = 0.28–0.88;
P = 0.014 and RR = 0.56, 95% CI = 0.31–1.00; P = 0.046, respectively)
but not in STEMI patients (RR = 0.87, 95% CI = 0.59–1.29; P = 0.49
and RR = 0.87, 95% CI = 0.58–1.29; P = 0.48), with negative inter-
action testing (Table 2). The risks of stroke, MI, stent thrombosis, or
urgent target vessel revascularization were not affected by access
site, with no signal of heterogeneity with respect to the initial clin-
ical presentation (Table 2 and see Supplementary material online,
eFigure S4).
Similarly, there was no significant interaction between access and
type of ACS with respect to bleeding endpoints, with the only excep-
tion for GUSTO moderate (Pint = 0.034) but neither GUSTO severe
nor the composite of moderate-to-severe GUSTO bleeding. Radial
access reduced BARC 2–5 and BARC 3–5 bleeding, owing to a signifi-
cant reduction of access site haemorrhagic complications (Table 2).
Fatal bleeding was rare, and it did not differ across access groups
within type of ACS.
Figure 2 Continued.
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Subgroup and sensitivity analyses
Figures 2 and 3 demonstrate the consistency of the two co-primary
outcomes in patients with NSTE-ACS and STEMI across predefined
subgroups. The effect of radial vs. femoral access appeared consistent
across age, sex, BMI, planned or actual use of prasugrel or ticagrelor
vs. clopidogrel, diabetes, renal function, history of peripheral vascular
disease, and tertiles of the centres’ annual volume of PCI.
Among STEMI but not NSTE-ACS patients, there was a signal for
heterogeneity for both co-primary outcomes across tertiles of the
centres’ percentage of radial PCI (see Supplementary material online,
eTable S3, overall volume of PCI and radial PCI per centre and tertiles
boundaries). Similar findings were noted for all-cause mortality
(see Supplementary material online, eFigure S5) but not for bleeding
(see Supplementary material online, eFigure S6). Finally, no inter-
action was noted between prior administration of UFH and the
occurrence of ST in the study groups, both in STEMI or NST-EACS
populations.
Discussion
The results of this prespecified sub-analysis of the MATRIX-Access
suggest that the overall trial results remain largely consistent in pa-
tients with NSTE-ACS and STEMI at presentation.6 There was no sig-
nificant interaction for any of the explored outcomes between the
access strategy (radial or femoral artery access) and initial clinical
presentation in terms of type of ACS (NSTE-ACS, STEMI). In patients
with NSTE-ACS, the use of radial access significantly reduced both
co-primary outcomes of MACE and NACE, as well as all-cause mor-
tality and cardiac mortality. In patients presenting with STEMI, the use
of radial access did not formally reduce all-cause or cardiac mortality,
Figure 3 ST-segment elevation myocardial infarction. *P-values are for trend across ordered groups. ACS, acute coronary syndrome; NSTE-ACS,
non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
*P-values are for trend across ordered groups.
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..albeit each endpoint numerically consistently favoured the radial ac-
cess, and no signal of heterogeneity was observed. As expected, the
overall event frequencies differ between NSTE-ACS and STEMI pa-
tients (for radial and femoral group combined). That is STEMI pa-
tients have more deaths, fewer MIs, more stent thrombosis and
more bleeds. The use of radial access for coronary angiography fol-
lowed by PCI significantly reduced the rate of BARC-actionable
(BARC 2–5) bleeding events across the entire spectrum of ACS irre-
spective of NSTE-ACS or STEMI at the time of presentation.
MATRIX-access is the largest (n¼ 8404) randomized trial to com-
pare radial and femoral access, including unselected patients at high
baseline and procedural risk. Our study results differ from those
observed in the RadIal Vs femorAL access for coronary intervention
(RIVAL) study, that reported a possible mortality benefit in STEMI
but not in NSTE-ACS patients with radial access, with positive inter-
action testing.4 This observation triggered concern within the inter-
ventional cardiology community, given the relatively scarce
comparative outcome data on radial vs. femoral access among pa-
tients with NSTE-ACS before the landmark RIVAL trial was pub-
lished, particularly as mortality even trended to be higher in patients
undergoing invasive management for NSTE-ACS via radial access. In
MATRIX-Access, a prerandomization stratification by type of ACS
(STEMI (n ¼ 4010 patients) and NSTE-ACS (n ¼ 4394 patients) re-
sulted in two study groups largely balanced for clinical and angio-
graphic characteristics. At variance with RIVAL, MATRIX-Access did
not provide any signal that NSTE-ACS patients may derive less bene-
fit than STEMI patients with radial as compared with femoral access.
Hence, the finding of a more favourable effect with radial access in
STEMI patients in RIVAL may be explained by random variation. An
alternative hypothesis is that operators who recruited patients with
NSTE-ACS in RIVAL had lower proficiency towards radial interven-
tion than those who recruited patients with STEMI.
The proportion of PCIs undertaken via radial access emerged as a
potential effect modifier in the overall MATRIX population for both
Figure 3 Continued.
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co-primary endpoints of MACE and NACE and overall mortality.
However, no such treatment modification effect was observed in our
current stratified analysis when NSTE-ACS patients were considered
separately. In addition, although the total volume of radial PCI-
procedures was higher for operators who recruited NSTE-ACS as
opposed to STEMI patients in RIVAL, the interaction between pre-
randomization diagnosis (STEMI vs. NSTE-ACS) and access site allo-
cation (radial vs. femoral access) remained highly significant (P ¼
0.0001) in a multivariable model of predictors of mortality, even after
adjustment for baseline variables, operator, and centre experience,
suggesting that it was independent of operator and centre radial ac-
cess experience. Unlike for patients with NSTE-ACS, the present
analysis confirmed that for patients with STEMI the proportion of
PCIs undertaken via radial access emerged as a treatment modifier
with respect to both co-primary endpoints and mortality. This sug-
gests that superiority in efficacy of radial over femoral access in
STEMI patients requires considerable expertise that can be met only
by high-volume radial operators.
Our present observations lend support to findings from previous
position articles, expert opinion papers from Europe and North
America, which endorse the preferential use of radial over femoral
access but caution against the unrestricted use of radial for STEMI
among inexperienced operators.7,12–16 The available data strongly
suggest that more efforts should be directed at increasing the adop-
tion of radial vascular access and training operators to acquire the ne-
cessary skills. As any procedure or interventions, there is a learning
curve with radial interventions, although several studies suggest that
the curve is not steep.17,18 Since radial access is beneficial across the
entire spectrum of ACS, operators may acquire experience in elect-
ive cases before engaging in more complex and acute cases.
Limitations of our analysis need to be considered. Although re-
ported subgroups were prespecified in the protocol and statistical
analysis plan, we did not adjust for multiple comparisons, increasing
the risk of type I error. Bleeding is an outcome that is dependent ac-
cording to various definitions. Using the BARC consensus definitions
for major bleeding, there were substantial reductions in bleeding in
both the STEMI and NSTE-ACS cohorts in MATRIX. Moreover,
these results were consistent when the GUSTO bleeding definitions
were applied. In addition, most centres participating in the MATRIX
trial were highly experienced in the radial technique; similar out-
comes may not apply in centres performing lower volumes of radial
access.
In conclusion, our results show that in unselected patients
undergoing invasive management for treatment of ACS, the use of ra-
dial compared with femoral access provided consistent benefit across
the whole spectrum of ACS without evidence that type of presenting
syndrome affected the results of the random access allocation.
Adequate operator experience emerged as treatment modifier in
STEMI but not NSTE-ACS patients, suggesting that operators willing
to transition from a default femoral to a default radial access should
first accrue enough transradial volume in elective cases.
Supplementary material
Supplementary material is available at European Heart Journal online.
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